TALLF - Overview: T-Cell Acute Lymphoblastic Leukemia (T-ALL), FISH

Test Catalog

Test Name

Test ID: TALLF    
T-Cell Acute Lymphoblastic Leukemia (T-ALL), FISH

Useful For Suggests clinical disorders or settings where the test may be helpful

Detecting a neoplastic clone associated with the common chromosome abnormalities seen in patients with T-cell acute lymphoblastic leukemia (T-ALL)

 

Identifying and tracking known chromosome abnormalities in patients with T-ALL and tracking response to therapy

 

An adjunct to conventional chromosome studies in patients with T-ALL

Reflex Tests Lists test(s) that may or may not be performed, at an additional charge, depending on the result and interpretation of the initial test(s)

Test IDReporting NameAvailable SeparatelyAlways Performed
_I099Interphases, 25-99No, (Bill Only)No
_I300Interphases, >=100 No, (Bill Only)No
_IL25Interphases, <25No, (Bill Only)No
_PADDProbe, +1No, (Bill Only)No
_PB02Probe, +2No, (Bill Only)No
_PB03Probe, +3No, (Bill Only)No
_PBCTProbe, +2No, (Bill Only)No

Testing Algorithm Delineates situation(s) when tests are added to the initial order. This includes reflex and additional tests.

This test includes a charge for application of the first probe set (2 FISH probes) and professional interpretation of results. Additional charges will be incurred for all reflex probes performed. Analysis charges will be incurred based on the number of cells analyzed per probe set. If no cells are available for analysis, no analysis charges will be incurred.

 

We recommend the following testing algorithm for patients with T-cell acute lymphoblastic leukemia (T-ALL):

-At diagnosis, conventional cytogenetic studies (CHRBM / Chromosome Analysis, Hematologic Disorders, Bone Marrow) and a complete T-ALL FISH panel should be performed.

-At follow-up, conventional cytogenetic studies (CHRBM / Chromosome Analysis, Hematologic Disorders, Bone Marrow) and targeted T-ALL FISH probes based on the abnormalities identified in the diagnostic study can be evaluated.

-If the patient clinically relapses, a conventional chromosome study is useful to identify cytogenetic changes in the neoplastic clone or the possible emergence of a new therapy-related myeloid clone.

 

Panel includes testing for the following abnormalities using the probes listed:

1p33 rearrangement, TAL1/STIL

t(5;14) TLX3/BCL11B

7q34 rearrangement, TRB

9p-,CDKN2A/D9Z1

t(9;22) or ABL1 amplification, BCR/ABL1

t(10;11), MLLT10/PICALM

11q23 rearrangement, MLL (KMT2A)

14q11.2 rearrangement, TRAD

17p-, TP53/D17Z1

 

When an MLL (KMT2A) rearrangement is identified, reflex testing will be performed to identify the translocation partner. Probes include identification of t(4;11)(q21;q23) AFF1/MLL, t(6;11)(q27;q23) MLLT4/MLL, t(9;11)(p22;q23) MLLT3/MLL, t(10;11)(p13;q23) MLLT10/MLL, t(11;19)(q23;p13.1) MLL/ELL or t(11;19)(q23;p13.3) MLL/MLLT1.

 

When a TRAD rearrangement is identified, reflex testing will be performed to identify the translocation partner. Probes include identification of t(8;14)(q24.1;q11.2) MYC/TRAD, t(10;14)(q24;q11.2) TLX1/TRAD, t(11;14)(p15;q11.2) LMO1/TRAD or t(11;14)(p13;q11.2) LMO2/TRAD.

 

When a TRB rearrangement is identified, reflex testing will be performed to identify the translocation partner. Probes include identification of t(7;10)(q34;q24) TRB/HOX11, t(7;11)(q34;p15) TRB/LMO1, t(7;11)(q34;p13) TRB/LMO2, or t(6;7)(q27;q34) TRB/MYB.

Method Name A short description of the method used to perform the test

Fluorescence In Situ Hybridization (FISH)

NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name

ALL (T-cell), FISH

Aliases Lists additional common names for a test, as an aid in searching

ABL1 amplification
17p- (17p deletion) or TP53
9p- (9p deletion) or CDKN2A or p16
t(10;11)(p13;q14) - MLLT10/PICALM or AF10/PICALM
t(10;11)(p13;q23) - MLLT10/MLL
t(10;14)(q24;q11.2) - TLX1/TRAD or HOX11/TRAD
t(11;14)(p13;q11.2) - LMO2/TRAD
t(11;14)(p15;q11.2) - LMO1/TRAD
t(11;19)(q23;p13.1) - MLL/ELL
t(11;19)(q23;p13.3) - MLL/MLLT1 or MLL/ENL
t(4;11)(q21;q23) - AFF1/MLL or AFF4/MLL
t(5;14)(q35;q32) - TLX3/BCL11B or HOX11L2/BCL11B
t(6;11)(q27;q23) - MLLT4/MLL or AF6/MLL
t(6;7)(q23;q34) - MYB/TRB
t(7;10)(q34;q24) - TRB/TLX1
t(7;11)(q34;p13) - TRB/LMO2
t(7;11)(q34;p15) - TRB/LMO1
t(8;14)(q24.1;q11.2) - MYC/TRAD
t(9;11)(p22;q23) - MLLT3/MLL or AF9/MLL
t(9;22)(q34;q11.2) - BCR/ABL1
T-cell receptor alpha/delta (TRAD) (14q11.2) rearrangement
T-cell receptor beta (TRB) (7q34) rearrangement
TAL1/STIL (1p33) rearrangement or TAL/SIL
MLL or KMT2A (11q23) rearrangement